CN105732595B - 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 - Google Patents
基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 Download PDFInfo
- Publication number
- CN105732595B CN105732595B CN201510975205.6A CN201510975205A CN105732595B CN 105732595 B CN105732595 B CN 105732595B CN 201510975205 A CN201510975205 A CN 201510975205A CN 105732595 B CN105732595 B CN 105732595B
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 23
- 239000003112 inhibitor Substances 0.000 title claims abstract description 13
- 101710121440 Proteinase-activated receptor 1 Proteins 0.000 title claims description 16
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 title claims 2
- 241001597008 Nomeidae Species 0.000 title abstract description 4
- 150000003505 terpenes Chemical class 0.000 title abstract description 4
- 235000007586 terpenes Nutrition 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 93
- 239000003814 drug Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 25
- 239000007788 liquid Substances 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 12
- 238000002347 injection Methods 0.000 claims description 12
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- -1 methoxyl methyl Chemical group 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 6
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 claims description 6
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 5
- 206010019280 Heart failures Diseases 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 5
- 125000004429 atom Chemical group 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 206010061216 Infarction Diseases 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 230000007574 infarction Effects 0.000 claims description 4
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical class 0.000 claims 1
- 230000001055 chewing effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 238000006735 epoxidation reaction Methods 0.000 claims 1
- 230000008707 rearrangement Effects 0.000 claims 1
- 239000007909 solid dosage form Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 208000032843 Hemorrhage Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 208000034158 bleeding Diseases 0.000 abstract description 4
- 230000000740 bleeding effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- 102100037136 Proteinase-activated receptor 1 Human genes 0.000 description 15
- 210000001772 blood platelet Anatomy 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 7
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000006837 decompression Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- AVXQPEKZIGPIJW-UHFFFAOYSA-N N3-cyclopropyl-7-[(4-propan-2-ylphenyl)methyl]pyrrolo[3,2-f]quinazoline-1,3-diamine Chemical compound C1=CC(C(C)C)=CC=C1CN1C(C=CC=2C3=C(N)N=C(NC4CC4)N=2)=C3C=C1 AVXQPEKZIGPIJW-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229930014626 natural product Natural products 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 0 CC[C@@](C)[C@@]1C(C)CC([*+]2IC2)N(C)CC1 Chemical compound CC[C@@](C)[C@@]1C(C)CC([*+]2IC2)N(C)CC1 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229940127218 antiplatelet drug Drugs 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KAWOEDMUUFFXAM-UHFFFAOYSA-N CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 Polymers CC1(C)CCCC2(C)C(C)C(C=O)=CCC21 KAWOEDMUUFFXAM-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 108010070519 PAR-1 Receptor Proteins 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- AZJUJOFIHHNCSV-KCQAQPDRSA-N Polygodial Polymers C[C@@]1([C@H](C(C=O)=CC2)C=O)[C@@H]2C(C)(C)CCC1 AZJUJOFIHHNCSV-KCQAQPDRSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 description 2
- 101710121439 Proteinase-activated receptor 4 Proteins 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- FPGPDEPMWUWLOV-UHFFFAOYSA-N polygodial Natural products CC1(C)CCCC2(C)C(C=O)C(=CC(O)C12)C=O FPGPDEPMWUWLOV-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 1
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- LNYLFYOXZJTAJF-JCEOFZDGSA-N C[C@@](CC[C@@H]1O)([C@H](CCC23OC2)[C@]1(C)C(O)=O)[C@@H]3/C=C/c(nc1)ccc1-c1cc(F)ccc1 Chemical compound C[C@@](CC[C@@H]1O)([C@H](CCC23OC2)[C@]1(C)C(O)=O)[C@@H]3/C=C/c(nc1)ccc1-c1cc(F)ccc1 LNYLFYOXZJTAJF-JCEOFZDGSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 1
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 description 1
- 101710186509 Partitioning defective 3 homolog Proteins 0.000 description 1
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 1
- 102100037133 Proteinase-activated receptor 3 Human genes 0.000 description 1
- 101710121425 Proteinase-activated receptor 3 Proteins 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- UVJHQYIOXKWHFD-UHFFFAOYSA-N cyclohexa-1,4-diene Chemical compound C1C=CCC=C1 UVJHQYIOXKWHFD-UHFFFAOYSA-N 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- AENCLWKVWIIOQH-UHFFFAOYSA-K cyclopentane;trichlorotitanium Chemical compound Cl[Ti](Cl)Cl.[CH]1C=CC=C1 AENCLWKVWIIOQH-UHFFFAOYSA-K 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000006462 rearrangement reaction Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960001064 vorapaxar sulfate Drugs 0.000 description 1
- NQRYCIGCIAWEIC-CKLVGUEFSA-N vorapaxar sulfate Chemical compound OS(O)(=O)=O.C(/[C@@H]1[C@H]2[C@H](C(O[C@@H]2C)=O)C[C@H]2[C@H]1CC[C@H](C2)NC(=O)OCC)=C\C(N=C1)=CC=C1C1=CC=CC(F)=C1 NQRYCIGCIAWEIC-CKLVGUEFSA-N 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/48—Aldehydo radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
Abstract
本发明涉及一种新的基于萜类衍生物的PAR‑1抑制剂、它们的制备方法以及包括它们和它们盐的药物组合物,以及所述PAR‑1抑制剂和它们的盐在制备用于预防和/或治疗血栓性疾病的药物中的用途。该化合物的结构式为:
Description
技术领域
本发明属于血液抗凝固技术领域,具体涉及一种新的基于萜类衍生物的PAR-1抑制剂、它们的制备方法以及包括它们和它们盐的药物组合物,以及所述PAR-1抑制剂和它们的盐在制备用于预防和/或治疗血栓性疾病的药物中的用途。
背景技术
在我国随着社会老龄化进程的加快,心血管病发病人数快速增长,该类疾病病程长、费用贵、致死致残率高。其中,由于血管栓塞引起的心血管疾病的发病率逐年上升,目前已经成为我国重大的公共卫生问题。
研究表明,血小板过度活化在血栓形成和血栓性疾病的发生和发展过程中起到重要作用。因此,抑制血小板的过度活化,减少血小板的黏附、聚集和释放是防治血栓性疾病的重要手段。目前,临床上用于防治血栓性疾病的抗血小板药物主要分为三大类,第一类是影响血小板代谢酶的药物,如环氧合酶抑制剂、血栓素A2(TXA2)抑制剂和磷酸二酯酶(PDE)抑制剂等;第二类是二磷酸腺苷(ADP)抑制剂,如噻氯匹定、氯吡格雷和替卡格雷等,通过抑制血小板的P2Y12受体,从而抑制血小板的聚集;第三类是血小板GP IIb/IIIa受体拮抗剂,如阿昔单抗和依替巴肽等,通过竞争性阻断纤维蛋白原与血小板表面GP IIb/IIIa受体结合,抑制血小板聚集。上述的传统抗血小板药物大多是通过抑制TXA2或ADP对抗血栓的形成,但由于TXA2和ADP均参与正常的止血过程,并在该过程中起到重要作用,因此TXA2或ADP抑制剂在阻滞病理性血栓形成过程的同时也影响了人体正常的止血功能,进而增加了患者发生出血的概率和风险。
血小板蛋白酶激活受体(Protease-activated receptor-1,PAR)是G蛋白偶联受体家族的一员,人类有PAR-1、PAR-2、PAR-3和PAR-4四种受体亚型,而分布于血小板表面的只有PAR-1和PAR-4。在凝血酶介导的血小板激活过程中,PAR-1起着更重要的作用。凝血酶在较低的浓度下便可激活PAR-1,并进一步激活血小板,导致血小板的快速聚集。抑制PAR-1受体能够阻断由凝血酶介导的血小板聚集和病理性血栓扩大的过程,但同时不会影响由TXA2和ADP参与的人体正常保护性止血过程。因此,PAR-1是一个理想的抗血小板药物靶点。
硫酸沃拉帕沙(Vorapaxar Sulfate)是由默沙东公司首创的PAR-1抑制剂,并已于2014年5月获得FDA批准上市,该药用于遭受心脏病发作的患者或腿部动脉有堵塞的患者,并可进一步降低心脏病发作和中风的风险。由于沃拉帕沙是通过抑制PAR-1阻断血小板的聚集, 因此该药物不会影响正常的止血过程,减少病人意外出血的风险。尽管沃拉帕沙具有良好的抗凝血活性,但是其存在结构复杂(具有7个手性中心),合成路线较长(其线性合成步骤为16步)和制备成本高昂的缺点。
天然产物由于其具有种类多样、结构复杂、手性明确、构象固定等特点,是研发新药的重要来源。以廉价易得的天然产物作为起始原料或药物前体,对其进行结构改造和修饰,可以迅速构建并大规模制备药物,同时还可有效降低生产成本。二萜类化合物穿心莲内酯和倍半萜类化合物水蓼二醛是常见的重要活性天然产物,其结构式如下:
其结构中手性中心的构象与沃拉帕沙结构中对应的关键手性中心构象完全一致。因此,以二萜类化合物和倍半萜类化合物为前体,在确保其关键手心中心构象保持不变的前提下,对其进行结构修饰与改造,是快速发现新的PAR-1抑制剂类药物的重要途径。
发明内容
针对上述现有技术的不足,本发明的目的是提供一种抗血小板抗血栓疾病的药物,该药物具有靶点明确、新颖,出血风险小,安全性高,活性效果突出,制备成本低廉等优势,可以作为治疗血栓性疾病的很有前景的药物。
为实现上述目的,本发明采用下述技术方案:
一种式(I)所示的化合物或其药学上可接受的盐,
其中,代表是单键或双键;R1和R2都分别代表:氢原子、卤素原子、羟基、(C1-C4)烷基、(C1-C4)烷氧基或(C1-C4)羟烷基;
或R1和R2共同形成一个双键;
或R1和R2共同形成一个具有3-7个原子的螺环或杂螺环;
R3和R4都分别代表:氢原子、羟基、(C1-C4)烷基、(C1-C4)羟烷基或(C1-C4)烷氧基;
或R3代表-C(O)R6、-C(O)OR6、-CO(O)R6、-COSOR6、-C(O)NR6R7;或R4代表-O(O)CR8、-OSOR8、-OSO2R8、-NHC(O)OR8、-NHC(O)R8、-NHCONHR8、-NHC(O)NR8R9、-NHSO2R8;
或R4代表氧原子,并与其相连的碳原子形成双键,即酮羰基;
R5代表卤素原子、三氟甲氧基或三氟甲基;
R6、R7、R8和R9独立选自氢原子、(C1-C6)烷基、酯基、羧酸基、苯基及苄基。
优选的,所述R1和R2都分别代表氢原子或(C1-C4)羟烷基,或R1和R2共同形成一个具有3-7个原子的杂螺环;R3为(C1-C4)羟烷基、甲氧甲基、甲酸基、甲酸甲酯基、醛基或甲酰胺基;R4为羟基、甲氧基或酮羰基;R5为卤素原子或三氟甲基。
进一步优选的,所述R1和R2共同形成杂螺环为三元氧环。
上述化合物的实例如下:
上述化合物药学上可接受的盐优选为上述化合物与无机酸,例如盐酸、硫酸、硝酸或氢溴酸形成的盐;或有机酸,例如甲磺酸、甲苯磺酸或三氟乙酸形成的盐。
除非另外指出,术语“(C1-C4)烷氧基”表示基团-O-R,其中R为(C1-C4)烷基。
术语“(C1-C4)羟烷基”表示被羟基取代的(C1-C4)烷基基团。
术语“螺环”表示R1和R2间通过共价键相连,并且与六元碳环上的螺原子共同形成一个环状结构。
术语“杂螺环”表示由R1、R2及螺原子构成的螺环中,包含有一个或多个杂原子,例如:氧原子、氮原子或硫原子等。
本发明另外提供了制备式(I)化合物的方法,它们可以如下面详述地得到。
上述化合物的制备方法包括使式(II)所示的化合物与式(III)所示的化合物反应得到式(I)所示的化合物。
其中,R1、R2、R3、R4和R5具有如前所述的定义。此外,R3和R4还可代表共同形成的4至8元碳环或杂环。
上述式(II)所示的化合物的制备方法为:以穿心莲内酯为起始原料,与三氧化二铝发生脱水重排反应制得式(IV)所示的化合物,将式(IV)的化合物通过与m-CPBA发生环氧化反应,再与2,2-二甲氧基丙烷发生缩醛化反应,最后与臭氧发生反应,制得式(II)所示的化合物。
其中,R1、R2、R3和R4具有如前所述的定义。此外,R3和R4还可代表共同形成的4至8元碳环或杂环。
本发明还提供上述化合物或其药学上可接受的盐在制备预防和/或治疗血栓性疾病的药物中的用途。例如在制备PAR-1抑制剂中的用途。这些血栓性疾病包括血栓形成、动脉粥样硬化、再狭窄症、高血压、心绞痛、心脏衰竭、紧急梗死、肾小球炎或周边血管疾病等。
本发明还提供一种药物组合物,该药物组合物包含上述的化合物或其药学上可接受的盐。
优选的,所述药物组合物还包含一种或多种药学上可接受的载体、赋形剂和/或稀释剂。
优选的,所述药物组合物包含一种或多种药学上或食品学上可接受的辅料。所用的辅料可为固态或液态。固态形式的制剂包括粉剂、片剂、分散颗粒、胶囊、药丸及栓剂。粉剂及片剂可包含约5%至约95%的活性成分。适当的固体辅料可以是碳酸镁、硬脂酸镁、滑石粉、糖或者乳糖。片剂、粉剂、药丸及胶囊为适于口服用的固态剂型。液态形式的制剂包括溶液、悬浮液及乳液,其实施例为非经肠注射用水溶液或水-丙二醇溶液,或添加甜味剂及造影剂的口服溶液。此外,还可制成注射用小水针、注射用冻干粉针、大输液或小输液。
优选的,所述药物组合物为固体口服制剂、液体口服制剂或注射剂。
进一步优选的,所述药物组合物为片剂、分散片、肠溶片、咀嚼片、口崩片、胶囊、糖衣剂、颗粒剂、干粉剂、口服溶液剂、注射用小水针、注射用冻干粉针、大输液或小输液。
我们已经发现,根据本发明制备的式(I)所示的化合物和它们药学上可接受的盐是可以用于制备预防和/或治疗血栓形成、动脉粥样硬化、再狭窄症、高血压、心绞痛、心脏衰竭、紧急梗死、肾小球炎或周边血管疾病的药剂。
因此,本发明的另一个主题是,一种治疗遭受血栓形成、动脉粥样硬化、再狭窄症、高血压、心绞痛、心脏衰竭、紧急梗死、肾小球炎或周边血管疾病的哺乳动物的方法,所述方法包括施用治疗有效量的如上所述的式(I)的化合物。
本文使用的术语“治疗有效量”表示,治疗、改善靶向的疾病或病症或者表现出可检测的治疗效果所需的治疗剂的量。
本发明的化合物在相当宽的剂量范围内是有效的。实际服用本发明式(I)所示的化合物的剂量可由医生根据有关的情况来决定。这些情况包括:被治疗者的身体状态、给药途径、年龄、体重、对药物的个体反应,症状的严重程度等。
在治疗过程中,上述式(I)化合物或其药学上可接受的盐可还以与至少一种其它心血管疾病药物合用。所涵盖的其它心血管疾病药物的原子组成或结构均异于式(I)的化合物。可与本发明新颖化合物组合使用的其它心血管疾病药物包括具有抗血栓形成、抗血小板聚集、抗动脉粥样硬化、抗再狭窄症及/或抗凝血活性的药物,这些药物可用于治疗与血栓形成相关的疾病,其包括血栓形成、动脉粥样硬化、再狭窄症、高血压、心绞痛、心律不整、心脏衰 竭、心肌梗死、肾小球炎、血栓形成性中风、血栓栓塞性中风、周边血管疾病、其他心血管疾病以及凝血酶及其受体在其中其病理作用的其他疾病。
本发明的有益效果:
(1)本发明的化合物具有靶点明确、结构新颖,出血风险小,安全性高,活性效果突出,制备成本低廉等优点,在制备治疗血栓性疾病的药物中具有很好的应用前景。
(2)制备本发明的化合物的起始原料为穿心莲内酯或水蓼二醛。其中,穿心莲内酯为常见的活性天然产物,廉价、易得。以穿心莲内酯为原料,在确保其关键手性中心构象不变的前提下,通过6至7步的结构修饰与改造,可快速、大规模制备并获得多种具有全新结构的化合物,同时具有良好的经济性。
具体实施方式
结合实施例对本发明作进一步的说明,应该说明的是,下述说明仅是为了解释本发明,并不对其内容进行限定。
实施例1:化合物I-1和I-2的制备
(1)步骤1:化合物1的制备
称取穿心莲内酯(500mg)置于圆底烧瓶中,加入吡啶加以溶解,向溶液中加入三氧化二铝(200mg),加热搅拌。反应结束后,体系降至室温,过滤除去氧化铝,减压蒸去溶剂,柱层析纯化(DCM/MeOH)得白色固体化合物1。
MS m/z 333(M+1);1H NMR(400MHz,DMSO)δ7.65(s,1H),6.74(dd,J=15.8,10.1Hz,1H),6.12(d,J=15.8Hz,1H),5.05(d,J=4.9Hz,1H),4.89(s,2H),4.73(s,1H),4.42(s,1H),4.14(dd,J=7.4,2.7Hz,1H),3.84(dd,J=10.9,2.6Hz,1H),3.31–3.14(m,2H),2.36(d,J=10.5Hz,2H),1.98(dd,J=14.1,7.5Hz,1H),1.72(d,J=13.0Hz,1H),1.65–1.50(m,2H),1.46–1.25(m,2H),1.23–1.11(m,2H),1.09(s,3H),0.76(s,3H).
(2)步骤2:化合物2的制备
取纯品化合物1(0.3mmol)和K2CO3(0.5mmol)置于圆底烧瓶中,加入二氯甲烷,体系降 温至0℃,缓慢加入m-CPBA,加毕,体系升至室温。反应结束后,加入纯水和二氯甲烷萃取,食盐水洗涤,硫酸镁干燥,过滤,减压蒸去溶剂,柱层析纯化得白色固体化合物2。
MS m/z 349(M+1);1H NMR(400MHz,Acetone)δ7.48(s,1H),6.49(dd,J=15.5,9.9Hz,1H),6.15(d,J=15.6Hz,1H),4.84(s,2H),4.53(s,1H),4.15(d,J=10.8Hz,1H),3.69(s,1H),3.38(dd,J=34.6,15.0Hz,3H),2.85(s,1H),2.72(d,J=3.5Hz,1H),2.51(d,J=4.5Hz,1H),2.20(d,J=9.8Hz,1H),1.93–1.52(m,6H),1.43(dd,J=26.2,13.5Hz,2H),1.23(s,4H),0.99(s,3H).
(3)步骤3:化合物3的制备
称取化合物2(6.91g)置于圆底烧瓶中,加入二氯甲烷溶解,相继加入2,2-二甲氧基丙烷(25mL)和对甲苯磺酸吡啶嗡(PPTS,800mg),反应结束后,加水,水层用二氯甲烷萃取,合并有机层,硫酸镁干燥,过滤,减压蒸去溶剂,柱层析纯化得白色固体化合物3。
MS m/z 389(M+1);1H NMR(400MHz,Acetone)δ7.49(s,1H),6.54(dd,J=15.6,9.9Hz,1H),6.17(d,J=15.7Hz,1H),4.85(d,J=1.4Hz,2H),4.06(d,J=11.6Hz,1H),3.45(dd,J=9.6,4.3Hz,1H),3.23(d,J=11.6Hz,1H),2.73(dd,J=4.7,1.6Hz,1H),2.53(d,J=4.7Hz,1H),2.26(d,J=9.9Hz,1H),2.09–1.96(m,2H),1.92–1.76(m,2H),1.71(s,1H),1.57(dd,J=12.9,4.0Hz,1H),1.53–1.41(m,2H),1.40–1.34(m,4H),1.28(s,4H),1.27–1.16(m,8H).
(4)步骤4:化合物4的制备
取化合物3(400mg)置于三囗烧瓶中,加入二氯甲烷和吡啶,低温条件下,通入O3,反应结束后,体系中加入二氯甲烷稀释,用水洗,硫酸镁干燥,过滤,减压蒸去溶剂,柱层析快速纯化,得无色油状化合物4,纯化后投下一步反应。
(5)步骤5:化合物7或8的制备
取化合物5或6(0.5mmol)置于烧瓶中,加入四氢呋喃溶解,低温条件下滴加正丁基锂的己烷溶液(2.5M/L),加毕,体系升至室温并继续搅拌,后加入化合物4的四氢呋喃溶液0.4mmol,搅拌至反应结束,滴加饱和氯化铵溶液淬灭反应,加入乙酸乙酯,有机层水洗,硫酸镁干燥,过滤,减压蒸去溶剂,柱层析纯化得白色固体化合物7或8。
化合物7:MS m/z 478(M+1);1H NMR(400MHz,CDCl3),δ:8.75(d,J=2Hz,1H),7.79(d,J=8Hz,1H),7.44(m,1H),7.35(d,8Hz,1H),7.24(m,2H),7.08(m,1H),6.54(d,J=3.2Hz,2H),4.11(d,J=11.6Hz,1H),3.51(dd,J=6Hz,4Hz,1H),3.30(d,J=11.6Hz,1H),2.92(d,J=4Hz,1H),2.61(d,J=4.4Hz,1H),2.41(t,J=4.4Hz,1H),1.96(m,2H),1.84(m,1H),1.76(m,1H),1.62(m,1H),1.52(m,2H),1.44(s,3H),1.38(s,3H),1.29(s,3H),1.25(s,3H),1.21(m,3H).
化合物8:MS m/z 527(M+1);1H NMR(400MHz,CDCl3)δ8.69(s,1H),7.70(dd,J=26.0,8.2Hz,3H),7.54(dd,J=18.4,7.6Hz,2H),7.18(d,J=8.5Hz,1H),6.47(s,2H),4.02(d,J=11.5Hz,1H),3.43(dd,J=9.8,3.8Hz,1H),3.22(d,J=11.7Hz,1H),2.84(d,J=3.4Hz,1H),2.53(d,J=4.0Hz,1H),2.34(d,J=5.6Hz,1H),2.05–1.84(m,2H),1.78(d,J=13.9Hz,1H),1.68(dd,J=13.4,5.2Hz,1H),1.58(dd,J=13.5,4.9Hz,1H),1.45(t,J=11.8Hz,2H),1.37(s,3H),1.30(d,J=8.1Hz,4H),1.20(d,J=15.1Hz,8H).
(6)步骤6:化合物I-1或I-2的制备
称取纯品化合物7或8(500mg)置于圆底烧瓶中,加入甲醇溶解,加入Amberlyst-15(100mg),搅拌,反应结束后,过滤、蒸去溶剂,柱层析纯化的白色产物化合物I-1或I-2。
I-1:MS m/z 438(M+1);1H NMR(400MHz,CDCl3),δ:8.74(s,1H),7.82(d,J=8Hz,1H),7.46(q,J=7.6Hz,1H),7.35(d,J=7.6Hz,1H),7.25(2H),7.11(t,J=8.4,1H),6.52(m,1H),6.52(m,1H),4.27(d,J=10.8Hz,1H),3.53(d,J=9.2Hz,1H),3.40(m,1H),3.21(m,2H),2.92(d,3.6Hz,1H),2.61(d,4Hz,1H),2.38(d,7.6Hz,1H),1.96(m,2H),1.81(m,1H),1.74(m,1H),1.62(m,1H),1.52(m,2H),1.30(s,3H),1.19(m,2H),1.04(s,3H).
I-2:MS m/z 488(M+1);1H NMR(400MHz,CDCl3)δ8.76(d,J=1.9Hz,1H),7.87–7.78(m,2H),7.75(d,J=7.6Hz,1H),7.63(dt,J=15.4,7.7Hz,2H),7.30–7.26(m,1H),6.50(dt,J=15.3,12.2Hz,2H),5.31(s,0H),4.27(d,J=10.7Hz,1H),3.59–3.47(m,1H),3.45–3.27(m,3H),2.92(d,J=3.6Hz,1H),2.62(d,J=4.3Hz,1H),2.39(d,J=9.1Hz,1H),1.95(d,J=11.2Hz,2H),1.88–1.79(m,1H),1.78–1.69(m,1H),1.69–1.60(m,1H),1.53(dd,J=18.2,7.1Hz,2H),1.32(s,3H),1.27–1.23(m,1H),1.21(s,1H),1.05(s,3H).
实施例2:化合物I-3和I-4的制备
将二茂二氯化钛85mg和锌粉40mg至于四氢呋喃溶液中,将化合物I-1或I-2(60mg)与1,4-环己二烯(80μL)的四氢呋喃溶液滴加至反应体系中。反应结束后,加入磷酸二氢钠饱和水溶液,搅拌至反应结束,随后过滤,加乙酸乙酯,水洗三遍,硫酸钠干燥,过滤,蒸除溶剂,硅胶柱层析分离纯化得到化合物I-3或I-4。
I-3:MS m/z 442(M+1);1H NMR(400MHz,CDCl3),δ:8.68(s,1H),7.84(dd,J=6Hz,2Hz,1H),7.45(dd,J=8Hz,6Hz,1H),7.34(d,J=7.6Hz,1H),7.29(1H),7.25(1H),7.08(t,J=8.4Hz,1H),4.10(d,J=11.2Hz,1H),3.74(m,3H),3.58(d,J=12Hz,1H),3.48(dd,J=6.4Hz,4Hz,1H),3.14(m,2H),2.59(m,1H),2.27(m,1H),1.84(m,3H),1.65(m,2H),1.49(m,2H),1.18(s,3H),0.92(s,3H),0.79(m,2H).
I-4:MS m/z 492(M+1);1H NMR(400MHz,CDCl3),δ:8.72(s,1H),7.88(d,J=8Hz,1H),7.79(s,1H),7.75(d,J=7.6Hz,1H),7.67(d,J=7.6Hz,1H),7.62(d,J=7.6Hz,1H),7.33(d,J=8Hz,1H),4.10(m,2H),3.78(d,J=12Hz,1H),3.59(d,J=12Hz,1H),3.51(dd,J=10.8Hz,4.8Hz,1H),3.15(d,J=12.4Hz,2H),2.92(br,2H),2.64(t,J=12.8Hz,1H),2.28(m,1H),2.04(s,1H),1.91(m,2H),1.66(m,3H),1.53(m,3H),1.25(s,3H),1.19(s,3H).
实施例3:化合物I-5和I-6的制备
化合物I-1(0.1mmol)溶于THF(2mL)中,加入NaH(0.2mmol),搅拌,滴入CH3I(0.25mmol),随后搅拌至反应结束。加入乙酸乙酯和水萃取,水洗涤,无水Na2SO4干燥,过滤,减压蒸去溶剂,柱层析纯化得I-5和I-6。
I-5:MS m/z 452(M+1);1H NMR(400MHz,CDCl3),δ:8.75(d,J=1.6Hz,1H),7.82(d,J=7.2Hz,1H),7.44(m,1H),7.35(d,J=8Hz,1H),7.24(m,2H),7.09(td,J=8.4Hz,2Hz,1H),6.54(m,2H),3.93(d,J=9.2Hz,1H),3.87(d,J=7.2Hz,1H),3.33(s,3H),3.28(d,J=9.2Hz,1H),2.94(d,J=3.6Hz,1H),2.60(d,J=4.4Hz,1H),2.39(d,J=9.2Hz,1H),1.95(s,1H),1.92(t,J=2Hz,1H),1.78(m,1H),1.70(m,1H),1.65(m,2H),1.56(dd,J=12.8Hz,4Hz,1H),1.51(m,1H),1.27(s,3H),1.21(m,2H),1.07(s,3H).
I-6:MS m/z 452(M+1);1H NMR(400MHz,CDCl3),δ:8.75(s,1H),7.83(d,J=7.2Hz,1H),7.44(dd,J=14.4Hz,8Hz,1H),7.35(d,J=7.6Hz,1H),7.27(m,2H),7.11(m,1H),6.54(m,2H),4.17(d,J=8.8Hz,1H),3.37(s,3H),3.26(m,2H),3.00(dd,J=12Hz,4.4Hz,1H),2.92(d,J=3.6Hz,1H),2.61(d,J=4.4Hz,1H),2.37(d,J=8.4Hz,1H),1.94(m,2H),1.70(m,2H),1.60(m,2H),1.52(m,1H),1.25(s,3H),1.21(m,2H),1.03(s,3H).
实施例4:化合物I-7、I-8和I-9的制备
(1)化合物I-7的制备
取化合物I-1(0.5mmol)溶于二氯甲烷中,低温条件下,加入TEMPO、K2CO3-NaHCO3缓冲液、TBAI(0.05mmol)及NCS,室温搅拌至反应结束,加入乙酸乙酯,用蒸馏水,无水Na2SO4干燥,过滤,减压蒸去溶剂,柱层析纯化,得白色固体I-7。
I-7:MS m/z 436(M+1);1H NMR(400MHz,CDCl3),δ:10.01(s,1H),8.85(d,J=2Hz,1H),8.07(dd,J=8Hz,2.4Hz,1H),7.62(m,4H),7.24(td,J=8Hz,1.6Hz,1H),6.48(m,2H),5.16(br,1H),2.80(d,J=4.4Hz,1H),2.54(d,J=4.8Hz,1H),2.44(d,J=8.8Hz,1H),1.97(m,4H),1.51(d,J=13.2Hz,1H),1.37(m,4H),1.12(s,3H),0.86(s,3H).
(2)化合物I-8的制备
将化合物I-7(0.4mmol)溶于异戊烷、叔丁醇和THF的混合溶剂中,冰浴条件下滴加NaClO2-NaH2PO4缓冲液,室温搅拌至反应结束。加乙酸乙酯,用蒸馏水洗涤,柱层析纯化,得白色固体I-8。
I-8:MS m/z 452(M+1);1H NMR(400MHz,CDCl3),δ:12.41(br,1H),8.84(d,J=2Hz,1H),8.08(dd,J=8Hz,2Hz,1H),7.59(m,4H),7.23(td,J=8.4Hz,1.6Hz,1H),6.48(m,2H),4.40(br,1H),3.12(dd,J=12Hz,4Hz,1H),2.81(d,J=4Hz,1H),2.57(d,J=4.4Hz,1H),2.36(d,J=7.6Hz,1H),2.07(m,1H),1.94(m,1H),1.84(m,1H),1.56(m,1H),1.46(m,1H),1.39(m,1H),1.31(s, 3H),1.26(m,2H),0.94(s,3H).
(3)化合物I-9的制备
取化合物I-8(0.5mmol)溶解于DMF中,随后加入K2CO3(1.25mmol),并慢慢滴加CH3I(2.5mmol),反应体系搅拌至反应完全。加入乙酸乙酯,用蒸馏水洗涤,无水Na2SO4干燥,柱层析纯化,得化合物I-9。
I-9:MS m/z 466(M+1);1H NMR(400MHz,CDCl3),δ:8.75(s,1H),7.81(d,J=4Hz,1H),7.43(q,J=4.8,1H),7.34(d,J=5.2Hz,1H),7.24(2H),7.08(t,J=5.2Hz,1H),6.53(br,2H),3.71(s,3H),3.25(d,J=8Hz,1H),3.16(td,J=8Hz,2.4Hz,1H),2.93(s,1H),2.63(d,J=2.8Hz,1H),2.39(d,J=5.2Hz,1H),2.10(m,1H),2.04(m,1H),1.95(m,2H),1.81(m,1H),1.71(d,J=9.2Hz,1H),1.52(d,J=7.2Hz,1H),1.46(s,3H),1.25(m,2H),0.92(s,3H).
实施例5:化合物I-10的制备
将化合物I-1(0.05mmol)溶于无水DCM,向反应体系中加入PCC(0.15mmol),搅拌至反应结束,过滤,滤液中加入乙酸乙酯,蒸馏水洗涤,Na2SO4干燥,减压蒸除溶剂,得白色固体。随后,加入DCM溶解,依次加入TEMPO、K2CO3-NaHCO3缓冲液、TBAI(0.005mmol) 及NCS,搅拌至反应结束。加入乙酸乙酯稀释,用蒸馏水洗涤,Na2SO4干燥,过滤减压蒸去溶剂,柱层析纯化得化合物I-10。
I-10:MS m/z 450(M+1);1H NMR(400MHz,CDCl3),δ:8.84(d,J=2Hz,1H),8.08(m,1H),7.61(m,4H),7.25(m,1H),6.50(m,2H),2.94(dd,J=14.8Hz,6Hz,1H),2.87(d,J=4Hz,1H),2.62(d,J=4.4Hz,1H),2.22(m,2H),1.90(m,2H),1.75(m,1H),1.61(d,J=10.8Hz,1H),1.49(m,2H),1.41(m,2H),1.27(s,3H),1.22(s,3H).
实施例6:化合物的生物活性(PAR-1抑制活性)测定
1.细胞培养
1.1细胞复苏
将HEK293-Gα15-PAR1细胞株(HD Biosciences稳转细胞株)从液氮罐内迅速取出,37℃水浴中不停摇晃,直到全部融化。迅速将细胞悬液加入预热的培养基(90%DMEM+10%FBS+1X Pen/Strep)中,放入离心机,1000转/分钟,离心10分钟。将离心管取出,弃去上清液,向离心管内加入新鲜预热的培养基,重悬细胞,将细胞悬液加入培养皿,37℃,5%CO2培养。1.2传代
当细胞长满至培养皿80~90%,用0.05%胰酶-EDTA轻轻洗细胞,去除部分消化液后孵育细胞2~3min,用新的培养基终止消化,枪头轻轻吹打细胞并将细胞重悬,通常情况下,每2~3天按1:4至1:8传代。
2.钙离子内流实验
2.1细胞板包被
实验前一天,在干净的384孔细胞板中加入1×Matrigel(Brand:BD,Cat#:356230),在37℃孵育30分钟,然后500转/分倒置离心30秒去除包被液。
2.2铺板
消化收集细胞沉淀,用培养基重悬至3×105细胞/mL,每孔50μL加入包被好的细胞板,后37℃,5%CO2孵育过夜。
2.3缓冲液配制
实验当天,配制新鲜的实验缓冲液和0.5×Calcium 4(Brand:MolecularDevices,Cat#:R8141)上样缓冲液。
2.4化合物的配制
先将30mM的DMSO储存液用DMSO稀释至10mM,后从10mM开始4倍倍比稀释,共10个浓度。将化合物的10个DMSO浓度梯度按1:20的比例加入到实验缓冲液中,制备成化合物的工作液(终反应浓度的5倍)。后将化合物的工作液转至384孔化合物板中待用。
阳性对照:将参照化合物SCH79797的40mM DMSO储存液稀释至2mM;
阴性对照:实验缓冲液配制的5%DMSO
2.5PAR-1激动剂haTRAP的配制
用实验缓冲液将激动剂haTRAP的10mM DMSO储存液稀释至18μM(终反应浓度3μM的6倍),后至少以25μl/孔转入384孔化合物板中待用。
2.6染料孵育
取出孵育过夜的细胞板,300转/分倒置离心30秒去除细胞培养基,每孔加入20μL新鲜配制的0.5×Calcium 4上样缓冲液,后37℃,5%CO2孵育1小时。
2.7加入化合物
按照布局从化合物板中转移5μL/孔的化合物工作液至细胞板中,然后再次置于37℃,5%CO2孵育15分钟。
2.8加激动剂读取荧光信号
按FLIPR设置程序从384孔化合物板(FLIPR)转5μl/孔激动剂到细胞板,同时读取细胞板中每孔的荧光信号。
3.数据分析
根据每块细胞板上的阳性对照和阴性对照的荧光信号值计算该细胞板上每孔中化合物的抑制率(%)。阳性对照含有高浓度的参照化合物(400μM的SCH79797),为100%抑制对照;阴性对照不含任何化合物,只有作为化合物溶剂的DMSO(1%DMSO),为0%抑制对照。将计算所得抑制率和相对应的化合物浓度导入相关软件作图,并按照4-PL剂量效应公式计算出该化合物的IC50值。参照化合物的IC50结果亦是检验每次实验质量的标准之一。
部分化合物的活性筛选结果如表1所示。
表1 部分化合物剂量效应结果
SCH79797 | I-1 | I-2 | I-3 | I-4 | I-5 | I-6 | I-7 | I-8 | I-9 | I-10 | |
Slope | 0.95 | 2.87 | 4.62 | 2.09 | 5.00 | 2.59 | 1.53 | 1.02 | 1.97 | 0.97 | 1.23 |
IC50(μM) | 8.71 | 7.76 | 7.95 | 8.91 | 8.76 | 7.07 | 10.96 | 3.52 | 31.64 | 0.66 | 19.71 |
活性筛选结果表明:化合物I-1至I-10均具有显著的体外抗PAR-1活性,其IC50值在0.66-19μM之间。其中,化合物I-7和I-9的体外PAR-1抑制活性较阳性对照药SCH79797有明显的提高,其IC50值分别为3.52μM和0.66μM。
Claims (14)
1.一种式(I)所示的化合物或其药学上可接受的盐,
其中,代表是单键或双键;R1和R2都分别代表:氢原子、卤素原子、羟基、(C1-C4)烷基、(C1-C4)烷氧基或(C1-C4)羟烷基;
或R1和R2共同形成一个双键;
或R1和R2共同形成一个具有3-7个原子的螺环或杂螺环;
R3代表氢原子、羟基、(C1-C4)烷基、(C1-C4)羟烷基或(C1-C4)烷氧基;
或R3代表-C(O)R6、-C(O)OR6或-C(O)NR6R7,其中R6、R7独立选自氢原子或(C1-C6)烷基;
R4代表羟基、(C1-C4)羟烷基或(C1-C4)烷氧基;
或R4代表氧原子,并与其相连的碳原子形成双键,即酮羰基;
R5代表卤素原子、三氟甲氧基或三氟甲基。
2.式(I)所示的化合物或其药学上可接受的盐,
所述R1和R2都分别代表氢原子或(C1-C4)羟烷基,或R1和R2共同形成一个具有3-7个原子的杂螺环;R3为(C1-C4)羟烷基、甲氧甲基、甲酸基、甲酸甲酯基、醛基或甲酰胺基;R4为羟基、甲氧基或酮羰基;R5为卤素原子或三氟甲基。
3.根据权利要求2所述的化合物或其药学上可接受的盐,其特征在于,所述R1和R2共同形成的杂螺环为三元氧环。
4.根据权利要求2至3任一项所述的化合物或其药学上可接受的盐,其特征在于,其是选自下列结构的化合物:
5.根据权利要求4任一项所述的化合物或其药学上可接受的盐,其特征在于,所述化合物药学上可接受的盐为所述化合物与无机酸或有机酸形成的盐。
6.权利要求1-3中的任一项所述的化合物或其药学上可接受的盐在制备PAR-1抑制剂中的用途。
7.权利要求1-3中的任一项所述的化合物或其药学上可接受的盐在制备预防和/或治疗血栓性疾病的药物中的用途。
8.根据权利要求7所述的用途,其特征在于,所述血栓性疾病包括血栓形成、动脉粥样硬化、再狭窄症、高血压、心绞痛、心脏衰竭、紧急梗死、肾小球炎或周边血管疾病。
9.一种权利要求1-5中的任一项所述的化合物或其药学上可接受的盐的制备方法,其特征在于,以穿心莲内酯为起始原料,与三氧化二铝发生脱水重排反应制得式(IV)所示的化合物,将式(IV)的化合物通过与m-CPBA发生环氧化反应,再与2,2-二甲氧基丙烷发生缩醛化反应,最后与臭氧发生反应,制得式(II)所示的化合物;
使式(II)所示的化合物与式(III)所示的化合物反应得到式(I)所示的化合物;
其中,R1、R2、R3、R4和R5如在权利要求1或2中所定义。
10.一种药物组合物,其包含权利要求1-5中任一项所述的化合物或其药学上可接受的盐。
11.根据权利要求10所述的药物组合物,其特征在于,所述药物组合物还包括一种或多种药学上可接受的载体、赋形剂和/或稀释剂。
12.根据权利要求10或11所述的药物组合物,其特征在于,所述药物组合物为固体口服制剂、液体口服制剂或注射剂。
13.根据权利要求12所述的药物组合物,其特征在于,所述药物组合物为片剂、胶囊、糖衣剂、颗粒剂、干粉剂、口服溶液剂、注射用小水针、注射用冻干粉针、大输液或小输液。
14.根据权利要求13所述的药物组合物,其特征在于,所述片剂为分散片、肠溶片、咀嚼片和口崩片。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510975205.6A CN105732595B (zh) | 2015-12-22 | 2015-12-22 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
US16/068,308 US10385041B2 (en) | 2015-12-22 | 2016-01-14 | Terpene derivative-based PAR1 inhibitor, preparation method thereof, and use in treatment of thrombotic diseases |
PCT/CN2016/070851 WO2017107262A1 (zh) | 2015-12-22 | 2016-01-14 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510975205.6A CN105732595B (zh) | 2015-12-22 | 2015-12-22 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105732595A CN105732595A (zh) | 2016-07-06 |
CN105732595B true CN105732595B (zh) | 2018-08-28 |
Family
ID=56296262
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510975205.6A Active CN105732595B (zh) | 2015-12-22 | 2015-12-22 | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10385041B2 (zh) |
CN (1) | CN105732595B (zh) |
WO (1) | WO2017107262A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110627710B (zh) * | 2019-09-29 | 2020-06-05 | 山东大学 | 一种新型par-1抑制剂及其制备方法和在预防和/或治疗血栓性疾病中的用途 |
CN110804012B (zh) * | 2019-10-30 | 2021-06-08 | 山东大学 | 一种还原缩硫醛或缩硫酮脱硫的方法 |
CN112759548B (zh) * | 2020-12-31 | 2021-11-02 | 山东大学 | 一种par-1抑制剂及其制备方法 |
CN115043820B (zh) * | 2022-05-27 | 2024-03-22 | 山东大学 | Par-1抑制剂及其类似物的制备方法和在血栓性疾病防治中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541782A (zh) * | 2006-10-04 | 2009-09-23 | 先灵公司 | 作为凝血酶受体拮抗剂的二环和三环衍生物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1802609A2 (en) * | 2004-10-08 | 2007-07-04 | Schering Corporation | Thrombin receptor antagonists |
CN101146781A (zh) * | 2005-03-31 | 2008-03-19 | 先灵公司 | 螺环凝血酶受体拮抗剂 |
WO2015026693A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
WO2015026685A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
-
2015
- 2015-12-22 CN CN201510975205.6A patent/CN105732595B/zh active Active
-
2016
- 2016-01-14 US US16/068,308 patent/US10385041B2/en active Active
- 2016-01-14 WO PCT/CN2016/070851 patent/WO2017107262A1/zh active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101541782A (zh) * | 2006-10-04 | 2009-09-23 | 先灵公司 | 作为凝血酶受体拮抗剂的二环和三环衍生物 |
Also Published As
Publication number | Publication date |
---|---|
US10385041B2 (en) | 2019-08-20 |
US20190023695A1 (en) | 2019-01-24 |
CN105732595A (zh) | 2016-07-06 |
WO2017107262A1 (zh) | 2017-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105732595B (zh) | 基于萜类衍生物的par-1抑制剂及其制备方法和在治疗血栓性疾病中的用途 | |
CA2570942C (en) | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament | |
CN113181339B (zh) | 一种醛基类化合物的药物用途 | |
TW200530225A (en) | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist | |
TW200534857A (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
JP6622205B2 (ja) | チエノピペリジン誘導体およびその使用 | |
JP2000319277A (ja) | 縮合ピラジン化合物およびその化合物を有効成分とする薬剤 | |
CN111803501B (zh) | 手性氯喹羟氯喹作为降低心脏毒性的用途 | |
KR20070086598A (ko) | 아릴- 및 헤테로아릴-치환 테트라히드로이소퀴놀린과노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기위한 이의 용도 | |
CN101139267A (zh) | 白藜芦醇衍生物、类似物及其制备方法和用途 | |
WO2021055589A1 (en) | Heteroaryl plasma kallikrein inhibitors | |
Huang et al. | Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents | |
CN110627710B (zh) | 一种新型par-1抑制剂及其制备方法和在预防和/或治疗血栓性疾病中的用途 | |
CN111658659B (zh) | 用于在预防和/或治疗缺血性脑血管疾病中使用的治疗剂 | |
CN102083826A (zh) | 磷脂酰肌醇3-激酶的抑制剂 | |
CN112074521B (zh) | 作为用于治疗血小板聚集的蛋白酶激活受体4(par4)抑制剂的化合物 | |
CN104583210B (zh) | 杂芳基化合物及其使用方法 | |
CN107400131A (zh) | 阿哌沙班衍生物及其制备方法和用途 | |
CN112759548B (zh) | 一种par-1抑制剂及其制备方法 | |
CN101851209B (zh) | 咪唑乙基香草酸醚、其制备方法及其医药用途 | |
JP5932827B2 (ja) | チアゾールアミン誘導体および抗ピコルナウイルス感染薬剤としてのその使用 | |
JPH04368379A (ja) | キサントン誘導体又はそのエステルを有効成分とする血栓予防治療剤 | |
CN110698445A (zh) | 一类3-胺烷基苯酞类化合物、其制备方法和用途 | |
JP2004529853A (ja) | 第Xa因子阻害剤の効率的な製造方法 | |
JP2018520128A (ja) | 重水素化チエノピペリジン誘導体、調製方法、及びその使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |